Topical tacrolimus in the management of atopic dermatitis in Japan

Masutaka Furue, Hiroshi Uchi, Yoichi Moroi, Sachiko Ogawa, Takeshi Nakahara, Kazunori Urabe

研究成果: Contribution to journalReview article査読

3 被引用数 (Scopus)

抄録

Atopic dermatitis (AD) is a common, chronic, relapsing, severely pruritic, eczematous skin disease. Topical steroids are the mainstay of treatment. However, the adverse effects of steroids on hormonal function are the major obstacle for their use as long-term topical therapy. Topical calcineurin inhibitors, such as tacrolimus, not only complement existing treatment options but also overcome some of the drawbacks of topical steroid therapy and fulfill the long-term needs of patients in preventing disease progression. Short- and long-term efficacy and safety of topical tacrolimus has been widely recognized and it is also accepted as a first-line treatment for the inflammation of AD. In order to reduce the possible long-term adverse effects, it is important to monitor the clinical dose in daily clinics.

本文言語英語
ページ(範囲)118-126
ページ数9
ジャーナルDermatologic Therapy
19
2
DOI
出版ステータス出版済み - 3 2006

All Science Journal Classification (ASJC) codes

  • 皮膚病学

フィンガープリント

「Topical tacrolimus in the management of atopic dermatitis in Japan」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル